LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (œGreenLight or the œCompany) today announced the closing of its previously announced...
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that it is initiating the final steps in...
GreenLight Biosciences is pushing ahead with plans to shrink its headcount. Shortly after the biotech put out news of a 51% reduction of its team, a notice in Massachusetts revealed 96 of the layoffs will happen at facilities in the state next month.
GreenLight Bioscience, the developer and manufacturer of RNA vaccines and therapeutics, is set to be acquired.
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (œGreenLight or the œCompany) today announced that the Company has entered into a definitive...
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and...
GreenLight Biosciences Releases Inaugural Sustainability Report
While biotech M&A may have cooled down over the past year, no one has told GreenLight Biosciences or Egitis Therapeutics, which are both mulling takeover offers.
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results